Finally, tirzepatide and cotadutide are two dual GLP1-RAs with gastric inhibitory polypeptide receptor activity and glucagon activity, respectively, which are being tested in phase II clinical trials for NASH patients (NCT04166773 and NCT04019561, respectively). The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatohepatitis.